|
|
|
|
Eisai, Current Status of the Development Programs of New Indications and Formulations of Aricept for Enhanci
3342 live jobs on PharmiWeb.com now Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, ?Eisai?) is currently focusing on three clinical development programs related to its mainstay product Aricept (donepezil...
|
|
|
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Pa
Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical...
|
|
|
Biogen Idec, Acorda Sign Collaboration Agreement For Fampridine-SR
Acorda to continue developing and commercializing Fampridine-SR in the US Biogen Idec and Acorda have signed an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS)...
|
|
|
Biogen Idec, Acorda enter pact to develop & commercialize MS therapy Fampridine-SR in outside US markets
Biogen Idec and Acorda Therapeutics, Inc.announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside the...
|
|
|
Fampridine-SR Licensed in markets outside the United States...more
Biogen Idec and Acorda Therapeutics, Inc.announced Wednesday that they have entered into an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis therapy, in markets outside...
|
|
|
Business in the Burbs: Acorda reaches agreement to cover foreign sales of MS drug
Acorda Therapeutics Inc., a Hawthorne-based biotech company, announced an agreement to develop, commercialize and gain regulatory clearances for its new multiple sclerosis drug in foreign markets with the assistance of another biotech...
|
|
|
BiomedReports: FDA Calendar Updates for Eisai (OTC:ESALY), King Pharma (NYSE:KG), Myriad Pharma (NASDAQ:MYRX)
(M2 PRESSWIRE via COMTEX) -- BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has new updates to it's database of FDA and...
|
|
|
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Pa
Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical...
|
|
|
Johnson & Johnson Buys Access to an Alzheimers Drug
Johnson & Johnson, the health care giant, will pay $1 billion to the Irish biotechnology company Elan to gain access to Alzheimers disease treatments, the companies said Thursday.Johnson & Johnson will acquire substantially all of...
|
|
|
Biogen Idec teams with Acorda Therapeutics on MS therapies
Tagged: Biogen Idec Business Health Health care Medicine Pharmaceutical industry Pharmaceuticals Biogen Idec and Acorda Therapeutics announce collaboration agreement to develop and commercialize MS therapy Fampridine-SR in markets...
|
|
|
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy F
Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S.Upfront Payment of $110 Million; Potential Deal Value Over $500 Million Acorda to Host Conference Call at 8:30 a.m. Eastern Time Today CAMBRIDGE, Ma. &...
|
|
|
Biogen Idec, Acorda sign licensing deal for Fampridine-SR
Biogen Idec acquired exclusive rights from Acorda Therapeutics to develop and commercialise experimental oral multiple sclerosis therapy Fampridine-SR (4-aminopyridine) outside the US, the companies announced on Wednesday.Analyst...
|
|
|
Biogen Idec Gains Ex-U.S. Rights to Acordas MS Therapy for $110M Up Front
Biogen Idecpaid $110 million up front for rights outside the U.S.to Acorda Therapeutics MS drug, Fampridine-SR. The compound is currently under FDA review as a therapy to improve walking ability in patients with multiple sclerosis...
|
|
|
Biogen Idec: shifting its multiple sclerosis pipeline
(Datamonitor via COMTEX) -- BGEN | Quote | Chart | News | PowerRating -- Biogen's MS pipeline has been in the spotlight this week due to negative Phase II data for CDP323 and the company's announcement of an agreement to develop and...
|
|
|
Deal Struck, Shares Stuck
Motley Fool Stock Advisor Since 2002, David and Tom Gardner have returned 29.22% while the S&P 500 returned -11.18%.Try Stock Advisor free for 30 days. Acorda Therapeutics (Nasdaq: ACOR) secured a decent upfront payment to...
|
|
|
Deal Struck, Shares Suck
Motley Fool Stock Advisor Since 2002, David and Tom Gardner have returned 29.26% while the S&P 500 returned -11.17%.Try Stock Advisor free for 30 days. Acorda Therapeutics (Nasdaq: ACOR) secured a decent upfront payment to...
|
|
|
SRS Applauds CCHIT for Listening to the Voice of the Physician
Companies mentioned in this article: SRSsoft MONTVALE, NJ -- (Marketwire) -- 07/02/09 -- SRS, the leader in high-performance hybrid EMR solutions, today announced its support for the recommendations released by the Certification...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept for Enhancing Patie
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
Companies mentioned in this article: Eisai Co., Ltd.TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America ...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , President & CEO: Haruo Naito 1. Sustained Release Tablets Eisai has completed a Phase III study of Aricept 23 mg sustained release (...
|
|
|
Biogen Gets Intl Rights to Acordas MS Drug
Cambridge, MA drug giant Biogen Idec (NASDAQ:BIIB) and Hawthorne, NY-based Acorda Therapeutics (NASDAQ:ACOR) announced today that Biogen Idec has acquired the rights to develop and commercialize Acordas multiple sclerosis drug, Fampridine-...
|
|
|
Acorda Therapeutics shares fall on concerns Biogen partnership could cramp buyout possibility
NEW YORK (AP) Shares of Acorda Therapeutics Inc.fell Wednesday after the company gave overseas rights to the experimental multiple sclerosis drug Fampridine-SR, though investors have been hoping for a buyout, according to a JPMorgan...
|
|
|
Zacks Analyst Blog Highlights: Wells Fargo, Bank of America, Acorda Therapeutics, Biogen Idec and Elan Corp
announces the list of stocks featured in the Analyst Blog.Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Wells...
|
|
|
CLC bio Expands Next Generation Sequencing Solutions with Digital Gene Expression by Tag Profiling
AARHUS, Denmark --(Business Wire)-- CLC bio today announced the release of new versions of the desktop application CLC Genomics Workbench, version 3.6 and the award-winning enterprise platform CLC Genomics Server, version 1.6.With this...
|
|
|
Zacks Analyst Blog Highlights: Wells Fargo, Bank of America, Acorda Therapeutics, Biogen Idec and Elan Corp
http://www.profit.zacks.com/ CHICAGO--(Business Wire)-- Zacks.com announces the list of stocks featured in the Analyst Blog.Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial...
|
